Eric Devroe

CIK: 0001950573

Transaction Breakdown

Open Market Buys (P)1 (7.7%)

High conviction signal

Open Market Sales (S)1 (7.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (30.8%)

Compensation grants

Other (G, F, J, C, D, …)7 (53.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRV

Acrivon Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

ACRV
Acrivon Therapeutics, Inc.
Aug 18, 2026
Sale(S)
Direct
604 shares at avg. $2.01$1K
ACRV
Acrivon Therapeutics, Inc.
May 18, 2026
Award(A)
Direct
73K shares-
ACRV
Acrivon Therapeutics, Inc.
May 14, 2026
Tax Payment(F)
Direct
613 shares at avg. $1.92$1K
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
186.7K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2026
Tax Payment(F)
Direct
723 shares at avg. $1.63$1K
ACRV
Acrivon Therapeutics, Inc.
Jan 13, 2026
Purchase(P)
Direct
10K shares at avg. $1.72$17K
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2025
Tax Payment(F)
Direct
613 shares at avg. $2.24$1K
ACRV
Acrivon Therapeutics, Inc.
Aug 14, 2025
Tax Payment(F)
Direct
613 shares at avg. $1.39$852.07
ACRV
Acrivon Therapeutics, Inc.
May 14, 2025
Tax Payment(F)
Direct
613 shares at avg. $1.14$698.82
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
140.5K shares-
ACRV
Acrivon Therapeutics, Inc.
Feb 14, 2025
Tax Payment(F)
Direct
724 shares at avg. $5.42$4K
ACRV
Acrivon Therapeutics, Inc.
Nov 14, 2024
Tax Payment(F)
Direct
613 shares at avg. $7.92$5K
ACRV
Acrivon Therapeutics, Inc.
Mar 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
90.1K shares-

		Type	Shares	Price		Ownership
Aug 18, 2026	ACRV Acrivon Therapeutics, Inc.	Sale(S)	604	$2.01	$1,214	Direct
May 18, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A)	72,981	-	$0	Direct
May 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	613	$1.92	$1,177	Direct
Mar 1, 2026	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	186,728	-	-	Direct
Feb 14, 2026	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	723	$1.63	$1,178	Direct
Jan 13, 2026	ACRV Acrivon Therapeutics, Inc.	Purchase(P)	10,000	$1.72	$17,218	Direct
Nov 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	613	$2.24	$1,373	Direct
Aug 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	613	$1.39	$852	Direct
May 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	613	$1.14	$699	Direct
Mar 1, 2025	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	140,540	-	-	Direct
Feb 14, 2025	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	724	$5.42	$3,924	Direct
Nov 14, 2024	ACRV Acrivon Therapeutics, Inc.	Tax Payment(F)	613	$7.92	$4,855	Direct
Mar 1, 2024	ACRV Acrivon Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	90,090	-	-	Direct

1-13 of 13 transactions

About Devroe Eric

Devroe Eric (SEC CIK 0001950573) files insider reports with the SEC as Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV).

Signal8 holds 13 ownership filings by Devroe Eric, all Form 4s, filed between Nov 18, 2024 and Aug 20, 2026. Those filings report 13 transactions, from Mar 1, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Devroe Eric's filings is in WATERTOWN, MA.

Recent filings by Devroe Eric

Aug 18, 2026: Open-market sale of ACRV shares (Form 4, code S).
May 18, 2026: Grant or award of ACRV shares (Form 4, code A).
May 14, 2026: Tax withholding of ACRV shares (Form 4, code F).
Mar 1, 2026: Grant or award of ACRV derivative securities (Form 4, code A).
Feb 14, 2026: Tax withholding of ACRV shares (Form 4, code F).

Other insiders filing for Acrivon Therapeutics, Inc. (ACRV)

Miller Mary, Chief Legal Officer
Levin Michaela, Chief Business Officer
Blume-Jensen Peter, President and CEO
Peterson Katharine, Chief Accounting Officer
Gamelin Erick, Chief Development Officer
Levy Adam D., Chief Financial Officer

How to read Form 4 transaction codes